These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 38666742)

  • 1. SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022- and 2023.
    Lustig Y; Canetti M; Indenbaum V; Peretz Y; Weiss-Ottolenghi Y; Margalit I; Asraf K; Levin T; Zuckerman N; Tomer E; Mandelboim M; Doolman R; Barda N; Regev-Yochay G
    Emerg Infect Dis; 2024 May; 30(5):1050-1052. PubMed ID: 38666742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
    Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
    Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine.
    Nguyenla XH; Bates TA; Trank-Greene M; Wahedi M; Tafesse FG; Curlin ME
    Emerg Infect Dis; 2024 Jun; 30(6):1282-1283. PubMed ID: 38669121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.
    Li H; Yang C; Yin L; Liu W; Zhang Z; Liu B; Sun X; Liu W; Lin Z; Liu Z; He P; Feng Y; Wang C; Wang W; Guan S; Wang Q; Chen L; Li P
    Emerg Microbes Infect; 2024 Dec; 13(1):2387447. PubMed ID: 39082740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sputnik V-Induced Antibodies against SARS-CoV-2 Variants during the Dissemination of the Gamma Variant in Venezuela.
    Franco C; Cornejo A; Rodríguez M; García A; Belisario I; Mayora S; Garzaro DJ; Jaspe RC; Hidalgo M; Parra N; Liprandi F; Zambrano JL; Rangel HR; Pujol FH
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection.
    Jiang XL; Song XD; Shi C; Yang GJ; Wang XJ; Zhang YW; Wu J; Zhao LX; Zhang MZ; Wang MM; Chen RR; He XJ; Dai EH; Gao HX; Shen Y; Dong G; Wang YL; Ma MJ
    Cell Rep; 2024 Jul; 43(7):114387. PubMed ID: 38896777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
    Lustig Y; Barda N; Weiss-Ottolenghi Y; Indenbaum V; Margalit I; Asraf K; Doolman R; Chalkias S; Das R; Elfatarany G; Harats D; Kreiss Y; Regev-Yochay G
    Vaccine; 2024 Sep; 42(22):126010. PubMed ID: 38806352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of the First National Standard for Neutralizing Antibodies against SARS-CoV-2 XBB Variants.
    Zhang X; Guan L; Li N; Wang Y; Li L; Liu M; He Q; Lu J; Zeng H; Yu S; Guo X; Gong J; Li J; Gao F; Wu X; Chen S; Wang Q; Wang Z; Huang W; Mao Q; Liang Z; Xu M
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific humoral immune response and XBB variants re-infection risk of hemodialysis patients after Omicron BA.5 infection in China.
    Mai W; Shen J; Ma F; Zhu J; Chen L; Lei Y; Yu P; Niu C; Wang F; Yan S; Mai X; He P; Liao L; Xiong X; Zheng Y; Liu Q; Huang Y; Wang Q; Liang J; Ji T
    Vaccine; 2024 Aug; 42(21):126108. PubMed ID: 39048466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.
    Wang Q; Mellis IA; Guo Y; Gherasim C; Valdez R; Gordon A; Ho DD; Liu L
    Cell Rep Med; 2024 Sep; 5(9):101701. PubMed ID: 39208800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
    Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies.
    Chen S; Zhang Z; Wang Q; Yang Q; Yin L; Ning L; Chen Z; Tang J; Deng W; He P; Li H; Shi L; Deng Y; Liu Z; Bu H; Zhu Y; Liu W; Qu L; Feng L; Xiong X; Sun B; Zhong N; Li F; Li P; Chen X; Chen L
    Signal Transduct Target Ther; 2024 Jul; 9(1):190. PubMed ID: 39039046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
    Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
    Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations.
    Song XD; Yang GJ; Shi C; Jiang XL; Wang XJ; Zhang YW; Wu J; Zhao LX; Wang MM; Chen RR; He XJ; Dai EH; Shen Y; Gao HX; Dong G; Ma MJ
    Int J Infect Dis; 2024 Oct; 147():107198. PubMed ID: 39117174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
    van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD;
    Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
    Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R
    J Infect Dis; 2024 Aug; 230(2):e279-e286. PubMed ID: 38349280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses.
    Wang Y; Hao A; Ji P; Ma Y; Zhang Z; Chen J; Mao Q; Xiong X; Rehati P; Wang Y; Wang Y; Wen Y; Lu L; Chen Z; Zhao J; Wu F; Huang J; Sun L
    Nat Commun; 2024 Jun; 15(1):5127. PubMed ID: 38879565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies.
    Wang X; Jiang S; Ma W; Zhang Y; Wang P
    Signal Transduct Target Ther; 2024 May; 9(1):123. PubMed ID: 38724561
    [No Abstract]   [Full Text] [Related]  

  • 20. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.